Correction: CAR-T cells inflict sequential killing of multiple tumor target cells (Cancer Immunol Res (2015) 3 (483–94) DOI: 10.1158/2326-6066.CIR-15-0048);CAR-T cells inflict sequential killing of multiple tumor target cells

Cancer Immunology Research

Volumn 3, Issue 5, 2015, Pages 483-494

  Davenport, Alexander J ^a,b,c   Jenkins, Misty R ^a,b   Cross, Ryan S ^a,b   Yong, Carmen S ^a,b   Prince, H Miles ^a   Ritchie, David S ^a,b,c   Trapani, Joseph A ^a,b   Kershaw, Michael H ^a,b   Darcy, Phillip K ^a,b   Neeson, Paul J ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; OVALBUMIN; PEPTIDE; SIINFEKL PEPTIDE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; PERFORIN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CYTOTOXIC T LYMPHOCYTE; MOUSE; MULTIPLE CANCER; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TARGET CELL DESTRUCTION; TRANSGENIC MOUSE; WESTERN BLOTTING; ANIMAL; GENETICS; IMMUNOLOGY; NEOPLASM; TUMOR CELL LINE;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 1; MICE, TRANSGENIC; NEOPLASMS; PERFORIN; RECEPTOR, ERBB-2; RECEPTORS, ANTIGEN; RECEPTORS, ANTIGEN, T-CELL;

EID: 84962217439     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-18-0027     Document Type: Erratum

References (35)

1. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013;5:177ra38.
2. Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, Stefanski J, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011;118:4817-28.
3. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19-28z CAR T-cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014;6:224ra25.
4. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368:1509-18.
5. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptormodified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365: 725-33.
6. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012;119: 2709-20.
7. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 2011;118:6050-6.
8. Kershaw MH, Westwood JA, Darcy PK. Gene-engineered T cells for cancer therapy. Nat Rev Cancer 2013;13:525-41.
9. Neeson P, Shin A, Tainton KM, Guru P, Prince HM, Harrison SJ, et al. Ex vivo culture of chimeric antigen receptor T cells generates functional CD8+ T cells with effector and central memory-like phenotype. Gene Ther 2010; 17:1105-16.
10. Darcy PK, Haynes NM, Snook MB, Trapani JA, Cerruti L, Jane SM, et al. Redirected perforin-dependent lysis of colon carcinoma by ex vivo genetically engineered CTL. J Immunol 2000;164:3705-12.
11. Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM, et al. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J Immunol 2002; 169:5780-6.
12. Bhat R, Watzl C. Serial killing of tumor cells by human natural killer cells - enhancement by therapeutic antibodies. PloS ONE 2007;2:e326.
13. Choi PJ, Mitchison TJ. Imaging burst kinetics and spatial coordination during serial killing by single natural killer cells. Proc Natl Acad Sci U S A 2013;110:6488-93.
14. Isaaz S, Baetz K, Olsen K, Podack E, Griffiths GM. Serial killing by cytotoxic T lymphocytes: T-cell receptor triggers degranulation, re-filling of the lytic granules and secretion of lytic proteins via a non-granule pathway. Eur J Immunol 1995;25:1071-9.
15. Lopez JA, Susanto O, Jenkins MR, Lukoyanova N, Sutton VR, Law RH, et al. Perforin forms transient pores on the target cell plasma membrane to facilitate rapid access of granzymes during killer cell attack. Blood 2013; 121:2659-68.
16. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR. T-cell receptor antagonist peptides induce positive selection. Cell 1994;76: 17-27.
17. Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM, et al. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood 2002;100:3155-63.
18. Wels W, Harwerth IM, Zwickl M, Hardman N, Groner B, Hynes NE. Construction, bacterial expression and characterization of a bifunctional single-chain antibody-phosphatase fusion protein targeted to the human erbB-2 receptor. Biotechnology 1992;10:1128-32.
19. Hagn M, Belz GT, Kallies A, Sutton VR, Thia KY, Tarlinton DM, et al. Activated mouse B cells lack expression of granzyme B. J Immunol 2012;188:3886-92.
20. Ke N, Wang X, Xu X, Abassi YA. The xCELLigence system for real-time and label-free monitoring of cell viability. Methods Mol Biol 2011;740:33-43.
21. Peper JK, Schuster H, Loffler MW, Schmid-Horch B, Rammensee HG, Stevanovic S. An impedance-based cytotoxicity assay for real-time and label-free assessment of T-cell-mediated killing of adherent cells. J Immunol Methods 2014;405:192-8.
22. Kawasaki A, Shinkai Y, Kuwana Y, Furuya A, Iigo Y, Hanai N, et al. Perforin, a pore-forming protein detectable by monoclonal antibodies, is a functional marker for killer cells. Int Immunol 1990;2:677-84.
23. Wang LX, Westwood JA, Moeller M, Duong CP, Wei WZ, Malaterre J, et al. Tumor ablation by gene-modified T cells in the absence of autoimmunity. Cancer Res 2010;70:9591-8.
24. Barnden MJ, Heath WR, Rodda S, Carbone FR. Peptide antagonists that promote positive selection are inefficient at T-cell activation and thymocyte deletion. Eur J Immunol 1994;24:2452-6.
25. Lopez JA, Jenkins MR, Rudd-Schmidt JA, Brennan AJ, Danne JC, Mannering SI, et al. Rapid and unidirectional perforin pore delivery at the cytotoxic immune synapse. J Immunol 2013;191:2328-34.
26. Burns WR, Zheng Z, Rosenberg SA, Morgan RA. Lack of specific gamma retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation. Blood 2009;114:2888-99.
27. Kageyama S, Tsomides TJ, Sykulev Y, Eisen HN. Variations in the number of peptide-MHC class I complexes required to activate cytotoxic T cell responses. J Immunol 1995;154:567-76.
28. Kimachi K, Croft M, Grey HM. The minimal number of antigen-major histocompatibility complex class II complexes required for activation of naive and primed T cells. Eur J Immunol 1997;27:3310-7.
29. Yewdell JW, Reits E, Neefjes J. Making sense of mass destruction: quantitating MHC class I antigen presentation. Nat Rev Immunol 2003;3: 952-61.
30. Ritchie DS, Neeson PJ, Khot A, Peinert S, Tai T, Tainton K, et al. Persistence and efficacy of second generation CART cell against the LeY antigeninacute myeloid leukemia. Mol Ther 2013;21:2122-9.
31. Cruz CR, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S, et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood 2013;122:2965-73.
32. Hoffmann P, Hofmeister R, Brischwein K, Brandl C, Crommer S, Bargou R, et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer 2005; 115:98-104.
33. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3:95ra73.
34. Ramsay AG, Johnson AJ, Lee AM, Gorgun G, Le Dieu R, Blum W, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008;118:2427-37.
35. John LB, Devaud C, Duong CP, Yong CS, Beavis PA, Haynes NM, et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res 2013;19: 5636-46.